Imeik Technology Development (SHE:300896) obtained medical device registration from China's medical products regulator for its new medical cross-linked sodium hyaluronate-hydroxypropyl methylcellulose gel.
The product is indicated for improving mild-to-moderate temporal depression in adults, according to a Wednesday aftermarket filing with the Shenzhen bourse.
The registration is valid until July 2031.
Shares of the biomedical products manufacturer rose 3% in recent trade.